Publication: 2158

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 33 (1) 13-21
Year:
2015
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
4
Parents:
342   1001  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, CA33601, CA076001, U10 CA180821, P30 CA016086, P50 CA058223, U10 CA180791, CA46368, CA32102, U10 CA180882, U10 CA180867, U10 CA180838, U10 CA180888, CA025224, CA31946  
Corr. Author:
 
Authors:
                                   
Networks:
CA043, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC007, LAPS-NY016, NY021, RI005, SCOR   
Study
CALGB-40603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Bc5, ORIGINAL REPORTS, Rapid Communications